>>He firmly believes that the company will earn 87 cents
this year and stands by his $24 target. I asked him why
he didn't increase his target when he increased his earnings
estimate from 40 cents to 87 cents to include Zicam and he
said that he increased his target from 14 to 21<<
<<<<I would be interested in feedback on the estimates in the following write up. Do they look reasonable?>>>
Dan,
The write up, IMO, is resonable, if Zicam is simply sold on
Drug Store shelves without any major media coverage. Due to
the nature of Zicam, and the fact that it will *most certainly*
be picked up by Major media...ie: Dateline, 20/20, Major News
organizations, I would throw any price projections out the
window :--)).
BTW, me ex-wife, who is quite skeptical of drugs in general,
tried Zicam, towards the end of her cold. She told me it helped
her sore throat the first night with one spray. The next day,
she sprayed twice, and was helped both with her symptons, and
generally felt better.
My bottom line: If Zicam's efficacy is shown and put on the
air though a major T.V. show and/or picked up by the major
news organizations, all bet's on a price target are off.
When ENTD went to $80 on promises years down the road,
GUMM could do the same with a proven product already on
the shelves. This is just my opinion, of course.
Skane |
